All posts by medical

Immunology

The pathophysiology of sepsis-2021 update: Part 1, immunology and coagulopathy leading to endothelial injury – DocWire News

This article was originally published here

Am J Health Syst Pharm. 2021 Oct 4:zxab380. doi: 10.1093/ajhp/zxab380. Online ahead of print.

ABSTRACT

DISCLAIMER: In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

PURPOSE: To provide an overview of current literature on the pathophysiology of sepsis, with a focus on mediators of endothelial injury and organ dysfunction.

SUMMARY: Sepsis is a dysregulated response to infection that triggers cascades of interconnected systems. Sepsis has been a significant cause of mortality worldwide, and the recent viral pandemic that may produce severe sepsis and septic shock has been a major contributor to sepsis-related mortality. Understanding of the pathophysiology of sepsis has changed dramatically over the last several decades. Significant insight into the components of the inflammatory response that contribute to endothelial injury and trigger coagulation pathways has been achieved. Similarly, characterization of anti-inflammatory pathways that may lead to secondary infections and poor outcome has illustrated opportunities for improved therapies. Description of an increasing number of important mediators and pathways has occurred and may point the way to novel therapies to address immune dysregulation. Pharmacists will need a fundamental understanding of the overlapping pathways of the immune response to fully prepare for use of novel treatment options. While pharmacists typically understand coagulation cascade how to utilize anticoagulants, the issues in sepsis related coagulopathy and role of mediators such as cytokines and complement and role of activated platelets and neutrophils require a different perspective.

CONCLUSION: Pharmacists can benefit from understanding both the cellular and organ system issues in sepsis to facilitate assessment of potential therapies for risk and benefit.

PMID:34605875 | DOI:10.1093/ajhp/zxab380

See the article here:
The pathophysiology of sepsis-2021 update: Part 1, immunology and coagulopathy leading to endothelial injury - DocWire News

Immunology

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers (SITC) 36th Anniversary Annual Meeting – Yahoo…

CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body, announced today three poster presentations at the Society for Immunotherapy of Cancer's 36th Anniversary Annual Meeting (SITC 2021), to be held both in Washington, D.C. at the Walter E. Washington Convention Center and virtually November 10-14, 2021.

Presentation Details:Title: A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer Poster #: 438Presenter: Dr. Sara I. Pai, M.D., Ph.D., associate professor of surgery, Division of Gastrointestinal and Oncologic Surgery; Director, Translational Research in Head and Neck Cancer Massachusetts General Hospital, Boston MADate: Saturday, November 13, 2021, Poster Hall (Hall E) 7 a.m.8:30 p.m. EST

Title: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies Poster #: 720Presenter: Dr. Christie Zhang, Ph.D., senior scientist, discovery and translational immunology, Cue Biopharma Date: Saturday, November 13, 2021, Poster Hall (Hall E) 7 a.m.8:30 p.m. EST

Title: Targeting engineered interleukin-2 (IL-2) to antigen specific T cells via novel biologic platformsPoster #: 793Presenter: Raymond J. Moniz, associate director, discovery and translational immunology, Cue BiopharmaDate: Friday, November 12, 2021, Poster Hall (Hall E) 7 a.m.8:30 p.m. EST

ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.

We look forward to presenting additional preclinical and clinical data that continues to validate the therapeutic potential of our IL-2 based CUE-100 series Immuno-STAT platforms and biologics, said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. We believe the data demonstrated in these posters show great promise in selective and specific tumor targeting for the treatment of multiple cancers and other life-threatening diseases.

Story continues

About the CUE-100 SeriesThe CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.

About SITCThe Society for Immunotherapy of Cancer (SITC) is the worlds leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

SITC is a 501(c)(3) not-for-profit medical professional society of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere.

Currently, SITC has more than 4,650 members who represent over 35 medical specialties in 63 countries around the world.

Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community.

About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body to transform the treatment of cancer, infectious disease and autoimmune disease. The companys proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform, is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information, visit https://www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the companys estimate of the period in which it expects to have cash to fund its operations; the companys belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells; and the companys business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the companys future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as believe, expect, may, will, should, would, could, seek, intend, plan, goal, project, estimate, anticipate, strategy, future, likely or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the companys strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the companys actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the companys limited operating history, limited cash and a history of losses; the companys ability to achieve profitability; potential setbacks in the companys research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (FDA) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the companys trials; negative or inconclusive results from the companys clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the companys reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the companys ability to obtain adequate financing to fund its business operations in the future; operations and clinical the companys ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the companys most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.com

Media ContactDarren Opland, Ph.D.LifeSci Communicationsdarren@lifescicomms.com

Originally posted here:
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers (SITC) 36th Anniversary Annual Meeting - Yahoo...

Immunology

Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer – StreetInsider.com

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

CAMBRIDGE, England--(BUSINESS WIRE)--Mogrify Limited (Mogrify), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Dr. Louise Modis as Chief Scientific Officer, following the recent completion of a $33 million USD Series A funding. Louise is an accomplished scientific leader in therapeutic discovery and development, and holds considerable experience in the progression of pre-clinical and clinical-stage assets, across various modalities and therapeutic areas. In her new role, Louise will lead the advancement of the Companys internal programs to help address high unmet clinical need in ophthalmology, immuno-oncology and other disease areas.

Louise has over 20 years experience in pre-clinical and clinical therapeutic research. Formerly Vice President of Immunology Research at GlaxoSmithKline (GSK), she led the generation and advancement of a pipeline of assets from target identification through to clinical proof-of-concept studies. Her roles at GSK included sponsorship of the Immunology Network, hosting external collaborators at GSK on sabbatical to nucleate and develop novel therapeutic concepts, championing in-licensing of assets, and representing GSK on the board of Sitryx. Prior to GSK, Louise led research teams at Boehringer Ingelheim Pharmaceuticals, and Millennium Pharmaceuticals (now Takeda), where she progressed therapeutic candidates targeted at immunology, oncology, and cardiovascular indications with unmet need. Dr. Modis holds a BSc (Biotechnology) from the National University of Ireland, Galway, earned her PhD (Developmental Hematology) at EMBL, Heidelberg, Germany and completed her postdoctoral fellowship at Harvard University, Boston.

Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: We are delighted to welcome Louise to the Mogrify Executive Team following a global search that considered drug discovery specialists from across Europe and the United States. Louises domain expertise, intellectual curiosity and passion for developing novel modalities capable of transforming clinical outcomes for patients suffering with degenerative diseases, make her an ideal fit to lead our internal programs through to first-in-human studies.

Dr. Louise Modis, Chief Scientific Officer, Mogrify, added: I am very excited to join Mogrify and to be able to deploy its powerful cell reprogramming platform to address the most immediate challenges of developing cost-effective ex vivo cell therapies in immuno-oncology. I am particularly enthused by the Companys development of novel in vivo therapeutic modalities and the opportunity to progress a number of in vivo reprogramming therapies rapidly through development into the clinic.

For further information about Mogrifys team, please visit:

https://mogrify.co.uk/team/leadership-team/

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005528/en/

Zyme CommunicationsMichelle Ricketts, PhDTel: +44 (0)7789 053 885Email: michelle.ricketts@zymecommunications.com

Source: Mogrify Limited

See the original post:
Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer - StreetInsider.com

Immunology

1700+ Graduates from Class of 2020 Expected to Return for Long-awaited In-Person Commencement Ceremony – UCF

Homecoming weekend will mean a little bit more to a special group of 1,700 Knights expected to return to campus to experience the milestone of an in-person commencement. For some, this graduation ceremony has been delayed more than a year.

Spring, Summer and Fall 2020 grads representing each of UCFs 13 colleges have registered for the ceremony, which will take place Nov. 5 at 9 a.m. at Addition Financial Arena and be livestreamed on UCFs YouTube channel.

Darin Edwards 97 10MS 11PhD who led the charge to create Modernas mRNA COVID-19 vaccine will serve as the keynote speaker for the 2020 Graduation Celebration.

In 2020, the Florida Board of Governors required all of Floridas state universities to hold virtual commencement ceremonies due to the COVID-19 pandemic. UCF conferred more than 18,000 degrees during its 2020 virtual commencement ceremonies.

During the ceremony, graduates will cross the stage during the traditional Pomp and Circumstance processional as their names are called. Each graduate is allowed up to four guests in attendance.

The deadline to participate in the Nov. 5 ceremony has passed. Participation in the ceremony is specifically for those graduates who missed in-person commencements experiences in 2020. Other graduates who would like to participate in a make-up ceremony may walk during the fall commencement ceremonies, which will be held Dec. 17-18.

Edwards is the director of immunology in the infectious disease group at Moderna, where he led the research and development on their mRNA COVID-19 vaccine. Additionally, he directs the immunology team in support of vaccine development programs and foundational research efforts, and leads work with external academic and industry collaborators including Modernas collaborative research efforts with the National Institute of Health, WHO, and Harvards pathogenesis working group.

Prior to joining Moderna in June 2019, Edwards served eight years for Sanofi Pasteur in Orlando, where he worked to develop vaccines against infectious diseases, including RSV, influenza, dengue, and yellow fever.

Edwards is a much-published researcher and academic speaker.Through his educational background at UCF, combined with his yearsof experience working on the development of next-generation vaccinetechnology, he has had the unique opportunity to make adirect and positive impact on global health.

He earned a bachelors inbiology, a masters in molecularbiology and microbiology and a doctorate inbiomolecular sciences from UCF, where he was also a Burnett Honors Scholar.

The health and well-being of all UCF graduates and their guests are the top priority of the university. Face coverings are expected while indoors for all attendees whether vaccinated or not, in accordance withthe latest CDC guidelines.

Continue reading here:
1700+ Graduates from Class of 2020 Expected to Return for Long-awaited In-Person Commencement Ceremony - UCF

Immunology

Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) – DocWire News

This article was originally published here

BMJ Open. 2021 Sep 30;11(9):e047133. doi: 10.1136/bmjopen-2020-047133.

ABSTRACT

PURPOSE: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) is a prospective cohort study in South Africa investigating the association between antiretroviral therapy (ART) use, preterm delivery (PTD) and small-for-gestational age (SGA) live births. PIMS main hypotheses are that ART initiation in pregnancy and ART-induced hypertension are associated with PTD and SGA respectively and that reconstitution of cellular immune responses in women on ART from before pregnancy results in increases in PTD of GA infants.

PARTICIPANTS: Pregnant women (n=3972) aged 18 years regardless of HIV status recruited from 2015 to 2016 into the overall PIMS cohort (2517 HIV-negative, 1455 living with HIV). A nested cohort contained 551 women living with HIV who were 24 weeks GA on ultrasound: 261 initiated ART before pregnancy, 290 initiated during the pregnancy.

FINDINGS TO DATE: Women in the overall cohort were followed antenatally through to delivery using routine clinical records; further women in the nested cohort were actively followed up until 12 months post partum, with data collected on maternal health (HIV care and ART use, clinical care and intercurrent clinical history). Other procedures conducted on the nested cohort included physical examinations (anthropometry, blood pressure measurement), assessment of fetal growth (ultrasound), maternal and infant phlebotomy for storage of plasma, RNA and peripheral blood mononuclear cells, collection of delivery specimens (placenta and cord blood) and infant 12-month developmental assessment. Preliminary findings have contributed to our understanding of risk factors for adverse birth outcomes, and the relationship between pregnancy immunology, HIV/ART and adverse birth outcomes.

FUTURE PLANS: Using specimens collected from study participants living with HIV throughout pregnancy and first year of life, the PIMS provides a valuable platform for answering a variety of research questions focused on temporal changes of immunology markers in women whose immune status is altered by HIV infection, and how ART initiated during the pregnancy affects immune responses. The relationship between these immunological changes with adverse birth outcomes as well as possible longer-term impact of exposure to ART in fetal and early life will be explored. Additionally, further active and passive follow-up of mothers and their infants is planned at school-going age and beyond to chart growth, morbidity and development, as well as changes in family circumstances.

PMID:34593488 | DOI:10.1136/bmjopen-2020-047133

Go here to read the rest:
Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) - DocWire News

Immunology

Global Immunology Drug Market 2021 Industry Insights and Major Players are Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune…

Comprehensive Global Immunology Drug Market from 2021 to 2027 analysis with precise projections and predictions, as well as full research solutions for strategic decision-making, are provided by Market Research Place studies. It also has separate chapters that include the regional studies to get a picture of the markets with future opportunities followed by the estimated yearly growth during the survey period from 2021 to 2027.

The report investigates the market by examining market dynamics, market trends, current trends, issues, challenges, competition analysis, and the firms involved. The study also goes into great detail on supply and demand assessments, as well as the participation of major industry players and market share growth statistics. All of the income margins, pricing, revenue proportions, and gross margins are determined in part.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketresearchplace.com/report-detail/216577/request-sample

It examines the market segments in the Immunology Drug market in depth:

The study takes into account a diverse variety of manufacturers, with business profiles of included

It provides granular analysis of the market segments of the Immunology Drug market:

The evaluation covers the major geographical areas that the industry operates in, including

ACCESS FULL REPORT: https://www.marketresearchplace.com/report/global-immunology-drug-market-research-report-2021-2027-216577.html

Main Points of the Report

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketresearchplace.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketresearchplace.com

Read the rest here:
Global Immunology Drug Market 2021 Industry Insights and Major Players are Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune...

Immunology

‘Last throw of the dice’ for Covid-19, claims Professor Luke O’Neill – Dublin Live

A leading immunology expert has given hope that Covid-19 may finally be on its "last throw of the dice".

The Delta variant completely changed how the public lives with Covid-19 given its higher transmissibility compared to previous strains of the disease.

But Professor Luke O'Neill of Trinity College told Today with Claire Byrne this morning that Delta "may be as bad as it gets" with vaccines holding firm against it.

"The vaccine is holding firmly against Delta is the message," he said.

A new study shows protection from the Pfizer vaccination remains at 90% six months after the second dose is administered.

However, Professor O'Neill adopted a more cautious tone when it came to giving booster shots to the wider population.

Professor O'Neill said: "It may change when it gets to nine months out or 12 months, then that might be slightly different."

He added if there's evidence of increased risk in six months time "then you may start giving a booster - it may well become a three-shot vaccine finally".

To get the latest breaking news straight to your inbox, sign up for our free newsletter

Read more:
'Last throw of the dice' for Covid-19, claims Professor Luke O'Neill - Dublin Live

Immunology

U of M research: vaccine offers greater protections for those who’ve already had COVID – MinnPost

The Star Tribunes Jeremy Olson writes: New University of Minnesota research is contesting a key argument against COVID-19 vaccination that people with prior coronavirus infections dont need further immunization to protect themselves. Comparing blood samples following COVID-19 vaccinations in 48 participants, the U researchers found that everyone gained key memory B cells capable of producing antibodies that fight off the coronavirus, but people with previous infections gained five times more of those cells. And in the world of immunology, more is better, said Marc Jenkins, a co-author and director of the Center for Immunology at the U Medical School.

WCCO-TV reports: Violence Free Minnesota released its 2020 homicide report on Friday, which analyzes relationship abuse in the state. In all, the report says that at least 30 people were killed due to intimate partner violence in 2020, and all but one of the victims identified as a woman. Of the 30 victims, 21 were killed by a current or former intimate partner, and nine victims were friends or family members attempting to intervene. Three of the victims were children.

For MPR, Mat Sepic writes: The lawyers prosecuting Kimberly Potter, the former police officer who killed Daunte Wright, are planning to introduce evidence showing that Potter was trained in the proper use of a Taser. As Potter, 49, and another Brooklyn Center officer tried to arrest Wright on a firearms warrant during a traffic stop April 11, he broke free and got back in his car. Potter is heard on video shouting Taser but instead pulls her handgun and shoots Wright in the chest. Potter is charged with first and second-degree manslaughter.

At FOX 9, Howard Thompson reports: A man is in custody after a police chase turned into a standoff with shots fired in Duluth, Minnesota on Friday. In tweets Friday evening, police say the suspect, who officers say was wanted following an attempted bank robbery and police chase, surrendered at about 8:30 p.m., hours after the incident began. According to police, the incident started at about 12:30 p.m. with a pursuit through the city and surrounding areas.

Article continues after advertisement

For MPR, Jon Collins writes: A pilot program launching Monday is aimed at freeing up Minneapolis police by using civilian city employees to enforce parking violations overnight. Parking control officers have traditionally enforced parking regulations during daylight hours and then handed duties off to the Minneapolis police for the night. Saray Garnett-Hochuli, interim director for regulatory services, said complaints about parking violations during these hours often went unaddressed because they were a low priority for police.

In the Pioneer Press, Betsy Helfand writes: A season that began with playoff aspirations will officially end with a fifth-place finish for the Twins, their first time winding up in the American League Central cellar since 2016, when they finished with the worst record in the majors. With an 11-6 loss to Kansas City on Friday night at Kauffman Stadium, the Twins (71-89) are three games behind the Royals (74-86) with two to play, locking them into fifth place in 2021 after winning division titles in each of the past two seasons.

Stephen Groves writes for the AP: South Dakota Gov. Kristi Noem on Friday defended her administrations handling of her daughters application for a real estate appraiser license, attempting to brush aside questions about a meeting she held last year that included her daughter, Kassidy Peters, and the state employee who was overseeing her application. I never once asked for special treatment for Kassidy, the Republican governor said in video posted on YouTube days after The Associated Press first reported on the meeting. The meeting happened after the Department of Labor and Regulation moved to deny Peters the license. Four months later, in November 2020, Peters received her certification as a residential appraiser, according to the department.

Here is the original post:
U of M research: vaccine offers greater protections for those who've already had COVID - MinnPost

Immunology

Opinion: In reponse to Robert Wise – Northside Sun

In all my columns concerning this pandemic, I never mentioned attorney Robert Wise in any way, but he has chosen not only to attempt to insult me but even intruded on the border of slander by several not-so clever ploys. First, he searched the discredited attack professional groups who make a living attacking anyone who challenges the orthodoxy. I recognized the MO immediatelythey all use the same worn-out material. While not actually saying so, it might be construed from the way he presented it that I lost my medical license when in truth, I retired from my neurosurgical practice in 2007. When one retires it is customary to also retire ones medical license. Not mandatory, but if you never plan to return to clinical practice why continue to pay the fees each year? I am almost 76 years oldwe do retire.

There is an old saying that If you cannot answer a mans arguments, all is not lostyou can still call him vile names. Many of those attacking those of us who believe in informed consent, that is, the right of the public to know all the facts concerning a proposed treatment, think like despots in totalitarian countries, assuming that only official or state controlled information should have access to the public square. One can always tell when a groups so-called information is tainted and cannot be openly defended. The controllers of information immediately use the courts or bureaucracies to control the debate, and they resort to personal attacks. We call that dirty pool or attack journalism.

My opinion, reading Wises latest nonsense being sold as reasoned argument, is that it is a cry of desperation and frustration at being intellectually unarmed. As for my credentials, I am the associate editor-in-chief of the neuroinflammatory section of the international journal Surgical Neurology International, one of the most read international neurosurgical journal in the world. In this position, I peer review submitted articles from experts on subjects dealing with immunology, neuroinflammation and infectious diseases affecting the brain and spinal cord.

I have around 60 articles published in a variety of scientific publications, a number dealing with immunology and the effects of vaccines on the central nervous system. My articles have been cited by other scientific journal articles over 1000 times. I am cited in a number of prestigious scientific papers as well as having a textbook chapter on immunoexcitotoxicity as a major pathophysiological mechanism for chronic traumatic encephalopathy (Biomarkers for Traumatic Brain Injuries, 2012, Dambinova SA et al eds). I have published articles on the pathophysiology of vaccine damage to the developing brain, articles that are widely cited in the scientific literature. I work with some of the top experts in immunology, vaccine complications and the effects of these vaccines on the nervous system. In addition, I have a two-part article published as an extensive primer for neurologists and neurosurgeons on immunology, both acquired and innate, which was reviewed by one of the top experts in immunology at UCLA Medical Center.

I have written six books on medical subjects and contributed chapters in four textbooks as well. What I find strange is that our illustrious attorney has, as far as I know, published nothing in the scientific literature on any of these subjects. All he can seem to do is tell emotional just-so stories and quote medical bureaucracies, such as the CDC and WHO, that are making millions off these and other vaccines. Both these bureaucracies are known to be corrupt to the core. The CDC has never treated a single patient for a covid-19 infection, yet they designed the protocol for most hospitals, that is generally rigidly enforced. Their protocol, in my opinion and others, was and continues to be responsible for a large percentage of the covid deaths in these hospitals.

The CDC also established the insane idea that infected people should stay at home, use no early treatments, until they were so sick, they require hospital or even ICU treatment. To compound this, they told people they should just take Tylenol and drink lots of liquids. Tylenol is a very dangerous drug and is responsible for a high percentage of serious complications seen in our hospitals. Each year we have over 700 deaths from Tylenol complications and during that same period there were only 2 deaths from Ivermectin. Every country that has initiated, as state policy, the use of Ivermectin has seen a dramatic and rapid drop in hospitalization and deaths. Some 27 randomized clinical studies from all over the world confirm that Ivermectin is very safe and dramatically reduces the death rate associated with this infection. Other early treatments, according to carefully controlled studies, have reduce death rates by as much as 80%, which if initiated by all states would have saved tens of thousands of lives. Instead, medical societies threaten our doctors with a loss of their license should they even speak anything but the incessant propaganda by the CDC and other medical bureaucracies. It is this massive control of medical information that is responsible, in my opinion and others, for the mass death associated with this virus.

Keep in mind that we would not be suffering from this never-ending pandemic had not Dr. Fauci, along with his cohorts, not supplied the Chinese communist bioweapons lab in Wuhan, China with millions of dollars in aid, as well as supplying critical information on viral gain-of-function from Dr. Ralph Barik in Chapel Hill North, Carolina.

Our Wise loves to quote stories of individuals who have died because they were unvaccinated, but he quotes none of the thousands of stories of those whose lives have been destroyed or ended by the vaccines, including the loss of a significant number of babies of pregnant women. In fact, according to an analysis of the data from the VAERS government reporting system, 4,524 cases of vaccine-linked myocarditis and pericarditis were reported from 9/3/2021. Of these, 385 occurred in children age 12 to 17 years of age. The figure continues to rise rapidly. Incredibly, 86% of healthy vaccinated boys required hospitalization. Those childrens lives have been ruined forever. They may never play sports, hike strenuous trails, or look forward to any semblance of a normal life, rather they can look forward to a life of cardiac incapacity of a progressive nature. All this over a vaccine that has been shown not to protect, was poorly tested before being released and used among an age group that was experiencing virtually no risk from this virus.

In my opinion and others, these children were the victims of the fear mongering and lying propaganda by the government agencies, medical associations, and the pharmaceutical-controlled media. As far as the so-called covid cases, there is no adequate testing to determine if a person has a clinical infection since the PCR test has been discontinued because it could not distinguish between the influenza virus and Covid-19. As we have seen all along, these so-called authorities are counting everything as being a covid hospital admission and/or death. As for the unvaccinated being the primary source of the viral transmission, we have learned that these authorities have a very interesting definition of being unvaccinatedeven a person who has had both doses of the vaccine, if they are admitted or die less than 14 days from the second dose they are labeledunvaccinated. This deception is used by all these vaccine promoting agencies.

I agree with a number of experts in this field, that it is the vaccinated that are primarily spreading this new virus variant, not the unvaccinated. Vaccinated parents are exposing their children in their home for very long periods. Fauci even admitted that the viral concentration in the nasopharynx of the vaccinated was very high and could be transmitted. Now we have most medical personnel acting as viral carriers and transmitters to their patients as they have been forced by hospitals and medical centers to be vaccinated.

Russell L. Blaylock, M.D.

See the original post here:
Opinion: In reponse to Robert Wise - Northside Sun

Immunology

AbbVie to Host Third-Quarter 2021 Earnings Conference Call – WITN

Published: Oct. 5, 2021 at 8:00 AM EDT|Updated: 7 hours ago

NORTH CHICAGO, Ill., Oct. 5, 2021 /PRNewswire/ --AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvieon Twitter, Facebook, Instagram, YouTubeand LinkedIn.

View original content:

SOURCE AbbVie

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Go here to read the rest:
AbbVie to Host Third-Quarter 2021 Earnings Conference Call - WITN